tirzepatide ban update FDA BANS Compounded Tirzepatide! Now What? fda ban on compounded tirzepatide

Mechanism of Action Pancreas: Increases glucose-dependent insulin secretion, decreases glucagon Brain: Enhances satiety Stomach: Slows gastric emptying Main Indications Type 2 diabetes mellitus Obesity/weight management Cardiovascular risk reduction Common Drugs Exenatide Liraglutide Semaglutide Dulaglutide Tirzepatide (dual GIP/GLP-1 agonist) Key Benefits Significant weight loss Low hypoglycemia risk Cardiovascular protection Major Side Effects Nausea/vomiting (most common) Pancreatitis (rare) Thyroid C-cell tumors (boxed warning) Contraindications Multiple Endocrine Neoplasia type 2 (MEN2) Personal/family history of medullary thyroid carcinoma #Pharmaceuticals #GLP1 #Diabetes #Obesity #Healthcare #Biotech #ClinicalResearch #Endocrinology #MedicalAffairs To view or add a comment, sign in More Relevant Posts New Experimental Study | Diabetes & Lipid Management Can Cinnamomum zeylanicum (Ceylon cinnamon) enhance conventional therapy in diabetes

BMI is part of the decision, but not the whole story BMI 30 often qualifies for weight management therapy

*Disclaimer: Wegovy and Ozempic are both registered trademarks of Novo Nordisk

Look AHEAD Research Group, Yeh HC, Bantle JP, Cassidy-Begay M, Blackburn G, Bray GA, et al

Bone Strength: Maintains bone strength and reduces the risk of fractures

Their other product, NA-941, regulates both GLP-1 and IGF-1 and is being evaluated in a Phase 2-/3 trial for the treatment of MASH